Human Papillomavirus (HPV)



Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2)


Conditions:   Human Papillomavirus;   Human Papillomavirus Infection
Intervention:  
Sponsors:   The Alfred;   Merck Sharp & Dohme Corp.
Not yet recruiting - verified December 2016


Txt2Protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men


Condition:   Human Papillomavirus
Interventions:   Behavioral: Txt2Protect;   Behavioral: Sexual Health Knowledge Control
Sponsors:   Northwestern University;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
Not yet recruiting - verified December 2016


Epidemiology of Human Papillomavirus Infection Among Women Living on the Maroni and the Oyapock Rivers


Condition:   Human Papillomavirus Viruses
Intervention:   Other: Cervico-Vaginal Smears analysis
Sponsor:   Centre Hospitalier de Cayenne
Completed - verified September 2016


Long Term Immune Memory Responses to Human Papillomavirus (HPV) Vaccination Following 2 Verses 3 Doses of Quadrivalent HPV Vaccine


Condition:   Human Papillomavirus
Intervention:   Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Sponsors:   University of British Columbia;   Merck Canada Inc
Not yet recruiting - verified November 2016


Investigation Into the Infectivity Levels of Human Papilloma Virus (HPV) in Tonsillar Tissue


Condition:   Human Papillomavirus, Palatine Tonsil
Intervention:   Genetic: HPV status and typing of tissue
Sponsor:   University of Derby
Enrolling by invitation - verified July 2016


Observational Follow up of Prior HPV Vaccinees


Condition:   Human Papillomavirus Virus
Intervention:   Other: venepuncture
Sponsor:   Public Health England
Recruiting - verified April 2017


Agreement Between Oral and Cervical Human Papillomavirus Infection in a French Cohort


Condition:   Human Papillomavirus-Related Cervical Carcinoma
Intervention:   Other: Agreement between oral and cervical HPV infection
Sponsor:   Institut de Cancérologie de Lorraine
Recruiting - verified December 2016


Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females


Conditions:   Human Papillomavirus;   Cervical Intraepithelial Neoplasia;   Persistent Infection
Intervention:   Biological: HPV-16/18 vaccine
Sponsors:   Shanghai Zerun Biotechnology Co.,Ltd;   Guangxi Center for Disease Control and Prevention
Recruiting - verified March 2017


Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females


Condition:   Human Papillomavirus
Interventions:   Biological: HPV vaccine;   Biological: Placebo
Sponsor:   Shanghai Zerun Biotechnology Co.,Ltd
Active, not recruiting - verified March 2017


Making Effective Human Papillomavirus (HPV) Vaccine Recommendations


Condition:   Human Papillomavirus
Interventions:   Behavioral: Participatory;   Behavioral: Efficient
Sponsors:   University of North Carolina, Chapel Hill;   Harvard Medical School;   North Carolina Department of Health and Human Services;   Pfizer
Completed - verified September 2016


Lubricant Investigation in Men to Inhibit Transmission of HPV Infection


Condition:   Human Papillomavirus Infection
Interventions:   Other: Carrageenan-based gel;   Other: Control gel
Sponsors:   McGill University;   Université de Montréal
Recruiting - verified August 2016


Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies


Conditions:   Human Papillomavirus (HPV)-Related Malignancies;   Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Intervention:   Drug: Ribavirin
Sponsor:   Memorial Sloan Kettering Cancer Center
Active, not recruiting - verified May 2017


The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases


Conditions:   Human Papillomavirus Infection;   Genital Warts
Intervention:  
Sponsors:   Jun Zhang;   Liuzhou center of disease prevention and control
Completed - verified July 2014


Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County


Condition:   Human Papilloma Virus Infection
Interventions:   Behavioral: Tailored education and referral;   Behavioral: Clinic training and patient reminders;   Behavioral: Clinic-level reminder systems
Sponsors:   University of California, Los Angeles;   Los Angeles County Department of Public Health
Enrolling by invitation - verified November 2016


Dynamics of Human PApilloma Virus Interactions; Internet-based Students HeAlth Research Enterprise


Condition:   Infection by Human Papilloma Virus
Intervention:   Other: Various biological sampling
Sponsors:   Institut Pasteur;   Université de Versailles Saint-Quentin-en-Yvelines;   centre national de référence pour les Papillomavirus Humains;   German Cancer Research Center
Completed - verified August 2016


A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)


Condition:   Human Papillomavirus Infection
Intervention:   Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified March 2017


Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients


Conditions:   Late Complication From Kidney Transplant;   Complication of Transplanted Liver;   Human Papillomavirus-Related Carcinoma
Intervention:   Drug: Quadravalent human papillomavirus vaccine
Sponsors:   The Hospital for Sick Children;   The Physicians' Services Incorporated Foundation;   Merck Sharp & Dohme Corp.
Active, not recruiting - verified December 2016


Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal


Conditions:   Metastatic Anal Canal Cancer;   Human Papillomavirus
Intervention:   Drug: DCF regimen
Sponsor:   Centre Hospitalier Universitaire de Besancon
Recruiting - verified August 2016


Genital HPV Infections Before and After Renal Transplantation


Condition:   Human Papillomavirus Infections
Intervention:  
Sponsors:   University Medical Center Nijmegen;   Dutch Kidney Foundation
Completed - verified October 2016


Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors


Conditions:   Cancer Survivor;   Prevention of Human Papillomavirus Infection
Interventions:   Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58);   Other: laboratory biomarker analysis;   Other: survey administration;   Other: medical chart review
Sponsors:   University of Alabama at Birmingham;   National Cancer Institute (NCI);   Merck Sharp & Dohme Corp.
Recruiting - verified October 2016


A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years


Conditions:   Human Papillomavirus;   HIV-1 Infection
Intervention:   Biological: Gardasil vaccine
Sponsors:   Kenyatta National Hospital;   University of Washington;   Merck Sharp & Dohme Corp.;   Kenya Medical Research Institute
Active, not recruiting - verified September 2016


Study of Gardasil in Mid-Adult Males (MAM)


Condition:   Human Papillomavirus
Intervention:   Biological: Gardasil
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Merck Sharp & Dohme Corp.
Active, not recruiting - verified January 2017


Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time


Conditions:   Oropharyngeal Cancer;   Human Papillomavirus
Intervention:  
Sponsors:   Johns Hopkins Bloomberg School of Public Health;   Icahn School of Medicine at Mount Sinai;   Oregon Health and Science University;   Dana-Farber Cancer Institute;   Johns Hopkins University
Completed - verified February 2017


Immunogenicity and Tolerability of V503 Versus GARDASIL


Condition:   Human Papillomavirus
Interventions:   Biological: 1 dose at Day 1, 1 dose at Month 2 and 1 dose at Month 6;   Biological: 1 dose at Day 1, 1 dose at Month 2 and 1 dose at Month 6
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)


Condition:   Human Papillomavirus Infection
Interventions:   Biological: V503;   Biological: Comparator: Menactra™ (Concomitant);   Biological: Comparator: Adacel™ (Concomitant);   Biological: Comparator: Menactra™ (Non-Concomitant);   Biological: Comparator: Adacel™ (Non-concomitant)
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017

Refine Your Search Advanced Search